Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial

Analyses suggest that despite higher incidence of any grade drug-related fatigue compared with placebo in patients with advanced NSCLC, pemetrexed maintenance does not impair patient-reported QoL.